BETA: Please send your feedback!

Seattle Genetics

NAS:SGEN

Biotechnology

$11.44bn
MID cap
$71.23 (2.99%)
23.8998%
since start of 2019
  • 3
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data Privacy
  • Consumer Health
  • Employee Satisfaction
  • Workplace Safety
  • Corp Gov
  • Ethical Practices
  • Conflict Materials
  • Forced Labor
  • Gender Diversity
  • 3
  • CF
  • PP
  • WC
  • DP
  • CH
  • ES
  • WS
  • CG
  • EP
  • CM
  • FL
  • GD
  • 1
  • 2
  • 3
  • 4
  • 5

About

Seattle Genetics, Inc. engages in the development and commercialization of monoclonal antibody-based therapies for cancer. Its product ADCETRIS, is an antibody-drug conjugate comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.
website

Headquarters

21823 30th Drive SE
Bothell, WA 98021

Executives

Name Title Gender
Jean I. Liu Executive VP-Legal Affairs & General Counsel Female
Vaughn B. Himes, PhD Chief Technology Officer Male
Perry Fell, PhD, MBA Founder Male
Clay B. Siegall, PhD Chairman, President & Chief Executive Officer Male
Eric L. Dobmeier Chief Operating Officer Male
Todd E. Simpson, CPA Chief Financial Officer Male
Jonathan Drachman, MD Chief Medical Officer, EVP-Research & Development Male
Christopher Pawlowicz Executive Vice President-Human Resources Male
Elaine Waller, PhD Executive Vice President-Regulatory Affairs Female
Peggy Pinkston Executive Director-Investor Relations Female

Mindful Investing Summary

  • 1
  • 2
  • 3
  • 4
  • 5
  • Carbon Footprint N/A
  • Pollution Prevention N/A
  • Water Conservation N/A
  • Data & Privacy Protection N/A
  • Consumer Health, Wellness & Safety N/A
  • Employee Ownership, Satisfaction, Benefits & Pay N/A
  • Workplace Health and Safety N/A
  • Integrity of Corporate Governance N/A
  • Ethical Practices N/A
  • Usage of Conflict Materials N/A
  • Forced Labor N/A
  • Diversity of Corporate Leadership 3

Seattle Genetics - Competitors and Related Companies

How Seattle Genetics stacks up to its peers in the Biotechnology industry or with competing business segments.

Seattle Genetics

NAS:SGEN

Biotechnology

$11.44bn
MID cap
$71.23 (2.99%)
23.8998%
since start of 2019
  • 3
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data Privacy
  • Consumer Health
  • Employee Satisfaction
  • Workplace Safety
  • Corp Gov
  • Ethical Practices
  • Conflict Materials
  • Forced Labor
  • Gender Diversity
  • 3
  • CF
  • PP
  • WC
  • DP
  • CH
  • ES
  • WS
  • CG
  • EP
  • CM
  • FL
  • GD
  • 1
  • 2
  • 3
  • 4
  • 5
Loading…